177 related articles for article (PubMed ID: 21576445)
1. Structure-analysis of the HIV-1 integrase Y143C/R raltegravir resistance mutation in association with the secondary mutation T97A.
Reigadas S; Masquelier B; Calmels C; Laguerre M; Lazaro E; Vandenhende M; Neau D; Fleury H; Andréola ML
Antimicrob Agents Chemother; 2011 Jul; 55(7):3187-94. PubMed ID: 21576445
[TBL] [Abstract][Full Text] [Related]
2. G140S/Q148R and N155H mutations render HIV-2 Integrase resistant to raltegravir whereas Y143C does not.
Ni XJ; Delelis O; Charpentier C; Storto A; Collin G; Damond F; Descamps D; Mouscadet JF
Retrovirology; 2011 Aug; 8():68. PubMed ID: 21854605
[TBL] [Abstract][Full Text] [Related]
3. Multiple genetic pathways involving amino acid position 143 of HIV-1 integrase are preferentially associated with specific secondary amino acid substitutions and confer resistance to raltegravir and cross-resistance to elvitegravir.
Huang W; Frantzell A; Fransen S; Petropoulos CJ
Antimicrob Agents Chemother; 2013 Sep; 57(9):4105-13. PubMed ID: 23733474
[TBL] [Abstract][Full Text] [Related]
4. The HIV-1 integrase mutations Y143C/R are an alternative pathway for resistance to Raltegravir and impact the enzyme functions.
Reigadas S; Anies G; Masquelier B; Calmels C; Stuyver LJ; Parissi V; Fleury H; Andreola ML
PLoS One; 2010 Apr; 5(4):e10311. PubMed ID: 20436677
[TBL] [Abstract][Full Text] [Related]
5. Lack of impact of pre-existing T97A HIV-1 integrase mutation on integrase strand transfer inhibitor resistance and treatment outcome.
Abram ME; Ram RR; Margot NA; Barnes TL; White KL; Callebaut C; Miller MD
PLoS One; 2017; 12(2):e0172206. PubMed ID: 28212411
[TBL] [Abstract][Full Text] [Related]
6. Dolutegravir-Selected HIV-1 Containing the N155H and R263K Resistance Substitutions Does Not Acquire Additional Compensatory Mutations under Drug Pressure That Lead to Higher-Level Resistance and Increased Replicative Capacity.
Anstett K; Fusco R; Cutillas V; Mesplède T; Wainberg MA
J Virol; 2015 Oct; 89(20):10482-8. PubMed ID: 26246578
[TBL] [Abstract][Full Text] [Related]
7. Impact of Y143 HIV-1 integrase mutations on resistance to raltegravir in vitro and in vivo.
Delelis O; Thierry S; Subra F; Simon F; Malet I; Alloui C; Sayon S; Calvez V; Deprez E; Marcelin AG; Tchertanov L; Mouscadet JF
Antimicrob Agents Chemother; 2010 Jan; 54(1):491-501. PubMed ID: 19901095
[TBL] [Abstract][Full Text] [Related]
8. Long-lasting persistence of integrase resistance mutations in HIV-2-infected patients after raltegravir withdrawal.
Charpentier C; Larrouy L; Matheron S; Damond F; Delelis O; Mouscadet JF; Campa P; Chêne G; Brun-Vézinet F; Descamps D;
Antivir Ther; 2011; 16(6):937-40. PubMed ID: 21900727
[TBL] [Abstract][Full Text] [Related]
9. HIV-1 resistance patterns to integrase inhibitors in antiretroviral-experienced patients with virological failure on raltegravir-containing regimens.
da Silva D; Van Wesenbeeck L; Breilh D; Reigadas S; Anies G; Van Baelen K; Morlat P; Neau D; Dupon M; Wittkop L; Fleury H; Masquelier B
J Antimicrob Chemother; 2010 Jun; 65(6):1262-9. PubMed ID: 20388636
[TBL] [Abstract][Full Text] [Related]
10. Characterization and structural analysis of HIV-1 integrase conservation.
Ceccherini-Silberstein F; Malet I; D'Arrigo R; Antinori A; Marcelin AG; Perno CF
AIDS Rev; 2009; 11(1):17-29. PubMed ID: 19290031
[TBL] [Abstract][Full Text] [Related]
11. Effects of raltegravir or elvitegravir resistance signature mutations on the barrier to dolutegravir resistance in vitro.
Seki T; Suyama-Kagitani A; Kawauchi-Miki S; Miki S; Wakasa-Morimoto C; Akihisa E; Nakahara K; Kobayashi M; Underwood MR; Sato A; Fujiwara T; Yoshinaga T
Antimicrob Agents Chemother; 2015 May; 59(5):2596-606. PubMed ID: 25691633
[TBL] [Abstract][Full Text] [Related]
12. Phenotypic susceptibility of HIV-2 to raltegravir: integrase mutations Q148R and N155H confer raltegravir resistance.
Smith RA; Raugi DN; Kiviat NB; Hawes SE; Mullins JI; Sow PS; Gottlieb GS;
AIDS; 2011 Nov; 25(18):2235-41. PubMed ID: 21971360
[TBL] [Abstract][Full Text] [Related]
13. Resistance to raltegravir highlights integrase mutations at codon 148 in conferring cross-resistance to a second-generation HIV-1 integrase inhibitor.
Goethals O; Van Ginderen M; Vos A; Cummings MD; Van Der Borght K; Van Wesenbeeck L; Feyaerts M; Verheyen A; Smits V; Van Loock M; Hertogs K; Schols D; Clayton RF
Antiviral Res; 2011 Aug; 91(2):167-76. PubMed ID: 21669228
[TBL] [Abstract][Full Text] [Related]
14. Biochemical and pharmacological analyses of HIV-1 integrase flexible loop mutants resistant to raltegravir.
Métifiot M; Maddali K; Naumova A; Zhang X; Marchand C; Pommier Y
Biochemistry; 2010 May; 49(17):3715-22. PubMed ID: 20334344
[TBL] [Abstract][Full Text] [Related]
15. Impact of combinations of clinically observed HIV integrase mutations on phenotypic resistance to integrase strand transfer inhibitors (INSTIs): a molecular study.
Cheung PK; Shahid A; Dong W; Lepik KJ; Montaner JSG; Brockman MA; Brumme ZL; Brumme CJ
J Antimicrob Chemother; 2022 Mar; 77(4):979-988. PubMed ID: 35061879
[TBL] [Abstract][Full Text] [Related]
16. Elvitegravir overcomes resistance to raltegravir induced by integrase mutation Y143.
Métifiot M; Vandegraaff N; Maddali K; Naumova A; Zhang X; Rhodes D; Marchand C; Pommier Y
AIDS; 2011 Jun; 25(9):1175-8. PubMed ID: 21505303
[TBL] [Abstract][Full Text] [Related]
17. Effect of raltegravir resistance mutations in HIV-1 integrase on viral fitness.
Hu Z; Kuritzkes DR
J Acquir Immune Defic Syndr; 2010 Oct; 55(2):148-55. PubMed ID: 20634701
[TBL] [Abstract][Full Text] [Related]
18. Virologic failure after 48 weeks of raltegravir-based regimen in low HIV-1 incidence setting.
Chehadeh W; Albaksami O; Al-Shammari S
Antivir Chem Chemother; 2020; 28():2040206620927908. PubMed ID: 32434393
[TBL] [Abstract][Full Text] [Related]
19. Three main mutational pathways in HIV-2 lead to high-level raltegravir and elvitegravir resistance: implications for emerging HIV-2 treatment regimens.
Smith RA; Raugi DN; Pan C; Coyne M; Hernandez A; Church B; Parker K; Mullins JI; Sow PS; Gottlieb GS;
PLoS One; 2012; 7(9):e45372. PubMed ID: 23028968
[TBL] [Abstract][Full Text] [Related]
20. Prevalence of primary resistance mutations to integrase inhibitors in treatment-naïve and -experienced patients infected with B and non-B HIV-1 variants.
Gutiérrez C; Hernández-Novoa B; Pérez-Elías MJ; Moreno AM; Holguín A; Dronda F; Casado JL; Moreno S
HIV Clin Trials; 2013; 14(1):10-6. PubMed ID: 23372110
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
